The Biotech Startups Podcast

In this episode of The Biotech Startups Podcast, we dive into how Nalu Bio CEO and co-founder Caitlyn Krebs is harnessing AI and the largely untapped endocannabinoid system (ECS) to build the first nonhormonal therapeutic for the two hundred million women living with endometriosis, while running an ultra-lean company with no lab, no university royalties, and a fully outsourced CRO/CMO model. She explains why CB1 and CB2 GPCRs are among pharma’s most druggable targets, how Nalu’s platform has sped drug development by 5x while doubling phase one success rates, and why the ECS may be medicine’s most overlooked frontier amid a women’s health landscape still dominated by opioids, chemical menopause, and invasive surgery.

In this episode of The Biotech Startups Podcast, Caitlyn Krebs traces her path from a gut-punch company shutdown on maternity leave — which unexpectedly forged a key cofounder relationship — through the digital health boom at Rock Health, to her role as COO at Neurotrack, where an eye-tracking Alzheimer's test launched to 137 countries within days and led to selling cognitive risk scores to Japanese life insurers as the only woman in the room. She closes out her pre-Nalu journey at BlueStar Genomics, where hard lessons in capital discipline and the dangers of scope creep shaped the focused, founder-ready mindset she brings to building Nalu Bio today.

In this episode of The Biotech Startups Podcast, Caitlyn Krebs, co-founder and CEO of Nalu Bio, traces her path from building the Bay Area's biotech ecosystem to operating at the cutting edge of science and business. She shares how launching BayBioNEST taught her what it really takes—beyond great science—to build durable companies, before diving into her time at Entelos, where she helped pioneer virtual patients and digital twins nearly twenty years before AI became a buzzword, and unpacks what BD actually means in biotech, from navigating black-box skepticism to running "bake-off" pilots that let the data speak for itself. The conversation then shifts to Tethys Bioscience, where Caitlyn helped bring a prediabetes diagnostic to market—winning over physicians, employers, and major payers like Aetna, United, and Cigna—only to watch a single Medicare/CMS misstep shutter a well-funded company, and what every founder can learn from that hard-won experience.

In this episode of The Biotech Startups Podcast, Caitlyn Krebs, co-founder and CEO of Nalu Bio, traces her journey from tagging endangered sea turtles on the Big Island of Hawaii to leading an AI-powered company designing novel cannabinoid-inspired small molecules for pain, inflammation, endometriosis, and metabolic disease. She reflects on being humbled at Brown University, where she fell in love with data analysis while studying leptin and early obesity science, then recounts jumping into the Bay Area’s dot-com boom as the third employee at a startup before, at just 27, taking the helm of BayBio and managing a 26-person board of biotech leaders—along the way crossing paths with a 20-year-old Stanford dropout named Elizabeth Holmes.

In this episode of The Biotech Startups Podcast, Siren Biotechnology CEO & Founder, Nicole Paulk unpacks why being a first-time female technical academic founder CEO — "the worst possible thing you could be" — was actually the best CEO training imaginable. She breaks down how her scrappy academic mindset stretched a $6M seed round across three and a half years, why going all-in on unglamorous CMC optimization was Siren Biotechnology's most important early decision, and why capital efficiency is a company-defining mindset, not just a financial strategy. Nicole also opens up about the loneliness of the founder CEO role, the toxic culture of "competitive complaining" at industry meetups, and the profound weight of Siren's recent FDA IND clearance — and what it means to be on the verge of dosing the very first brain cancer patient at UCSF.